The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Plasmacytoma


Psychiatry related information on Plasmacytoma


High impact information on Plasmacytoma


Chemical compound and disease context of Plasmacytoma

  • The growth of primary plasmacytomas in transplant that is dependent on the pristane-conditioned peritoneal environment was not inhibited by indomethacin treatment [3].
  • The many binding studies of monoclonal immunoglobulin (Ig) produced by plasmacytomas have found no universally common binding properties, but instead, groups of plasmacytomas with specific antigen-binding activities to haptens such as phosphorylcholine, dextrans, fructofuranans, or dinitrophenyl [11].
  • The role of indomethacin in inhibiting plasmacytoma development was not established; two possibilities are that it inhibits production of mutagenic and tissue destructive oxidants by inflammatory cells, and it inhibits prostaglandin synthesis and intracellular production of oxidant biproducts [3].
  • The present study deals with the identification of effector-cytotoxic cells that may be developed as a result of chemotherapy-induced tumor regression and their possible potentiation by active, specific immunization with melphalan- and glutaraldehyde-treated MOPC-315 plasmacytoma cells [12].
  • BALB/c mice with the plasmacytoma MOPC 104E were cured of palpable tumors (6-15x10(7) cells) with a single injection of cyclophosphamide (10 mg/kg) [13].

Biological context of Plasmacytoma


Anatomical context of Plasmacytoma


Gene context of Plasmacytoma

  • Since IL-6 functions as a potent growth factor for murine plasmacytomas, over-expression of abnormal IL-6-R may function as a positive selection element for the development of certain plasmacytomas [23].
  • Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 [24].
  • These results demonstrate that mast cell-derived Ang-1 promotes the growth of plasmacytomas by stimulating neovascularization and provide further evidence supporting a causal relationship between inflammation and tumor growth [25].
  • Rapamycin, a specific inhibitor of FRAP, did not inhibit growth of plasmacytoma cell lines [26].
  • However, the kappaB binding complex in the plasmacytomas that were examined lacked c-Rel and instead contained only a p50-related protein [27].

Analytical, diagnostic and therapeutic context of Plasmacytoma


  1. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R., Magrath, I. Nat. Genet. (1993) [Pubmed]
  2. A second B cell-specific enhancer 3' of the immunoglobulin heavy-chain locus. Pettersson, S., Cook, G.P., Brüggemann, M., Williams, G.T., Neuberger, M.S. Nature (1990) [Pubmed]
  3. Inhibition of plasmacytoma development in BALB/c mice by indomethacin. Potter, M., Wax, J.S., Anderson, A.O., Nordan, R.P. J. Exp. Med. (1985) [Pubmed]
  4. Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus. Clynes, R., Wax, J., Stanton, L.W., Smith-Gill, S., Potter, M., Marcu, K.B. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  5. Hydroxymethyluracil DNA glycosylase in mammalian cells. Hollstein, M.C., Brooks, P., Linn, S., Ames, B.N. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  6. AID is required for c-myc/IgH chromosome translocations in vivo. Ramiro, A.R., Jankovic, M., Eisenreich, T., Difilippantonio, S., Chen-Kiang, S., Muramatsu, M., Honjo, T., Nussenzweig, A., Nussenzweig, M.C. Cell (2004) [Pubmed]
  7. Deletions are associated with somatic rearrangement of immunoglobulin heavy chain genes. Cory, S., Adams, J.M. Cell (1980) [Pubmed]
  8. Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Ohno, S., Babonits, M., Wiener, F., Spira, J., Klein, G., Potter, M. Cell (1979) [Pubmed]
  9. Transcription of specific genes in isolated nuclei by exogenous RNA polymerases. Sklar, V.E., Roeder, R.G. Cell (1977) [Pubmed]
  10. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Strasser, A., Harris, A.W., Bath, M.L., Cory, S. Nature (1990) [Pubmed]
  11. Restricted immunoglobulin variable region (Ig V) gene expression accompanies secondary rearrangements of light chain Ig V genes in mouse plasmacytomas. Diaw, L., Siwarski, D., Coleman, A., Kim, J., Jones, G.M., Dighiero, G., Huppi, K. J. Exp. Med. (1999) [Pubmed]
  12. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy. Adler, A., Keisari, Y., Ofir, R. J. Natl. Cancer Inst. (1985) [Pubmed]
  13. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity. Lubet, R.A., Carlson, D.E. J. Natl. Cancer Inst. (1978) [Pubmed]
  14. Transposition of the immunoglobulin heavy chain enhancer to the myc oncogene in a murine plasmacytoma. Corcoran, L.M., Cory, S., Adams, J.M. Cell (1985) [Pubmed]
  15. A conserved sequence at c-myc oncogene chromosomal translocation breakpoints in plasmacytomas. Piccoli, S.P., Caimi, P.G., Cole, M.D. Nature (1984) [Pubmed]
  16. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Madisen, L., Groudine, M. Genes Dev. (1994) [Pubmed]
  17. DNA rearrangement and constitutive expression of the interleukin 6 gene in a mouse plasmacytoma. Blankenstein, T., Qin, Z.H., Li, W.Q., Diamantstein, T. J. Exp. Med. (1990) [Pubmed]
  18. Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals. Keath, E.J., Caimi, P.G., Cole, M.D. Cell (1984) [Pubmed]
  19. Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas. Cohen, J.B., Unger, T., Rechavi, G., Canaani, E., Givol, D. Nature (1983) [Pubmed]
  20. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H. Nature (1988) [Pubmed]
  21. Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription. Maier, H., Ostraat, R., Gao, H., Fields, S., Shinton, S.A., Medina, K.L., Ikawa, T., Murre, C., Singh, H., Hardy, R.R., Hagman, J. Nat. Immunol. (2004) [Pubmed]
  22. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. Stamenkovic, I., Seed, B. J. Exp. Med. (1988) [Pubmed]
  23. Functional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesis. Sugita, T., Totsuka, T., Saito, M., Yamasaki, K., Taga, T., Hirano, T., Kishimoto, T. J. Exp. Med. (1990) [Pubmed]
  24. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. Nishimoto, N., Ogata, A., Shima, Y., Tani, Y., Ogawa, H., Nakagawa, M., Sugiyama, H., Yoshizaki, K., Kishimoto, T. J. Exp. Med. (1994) [Pubmed]
  25. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. Nakayama, T., Yao, L., Tosato, G. J. Clin. Invest. (2004) [Pubmed]
  26. Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Bliskovsky, V., Ramsay, E.S., Scott, J., DuBois, W., Shi, W., Zhang, S., Qian, X., Lowy, D.R., Mock, B.A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  27. Identification of a novel NF-kappaB p50-related protein in B lymphocytes. Phillips, R.J., Gustafson, S., Ghosh, S. Mol. Cell. Biol. (1996) [Pubmed]
  28. Enhancement of growth of allogeneic mouse tumor by the IgG1 fraction of alloantibody preparations. Harris, T.N., Harris, S., Henri, E.M., Farber, M.B. J. Natl. Cancer Inst. (1978) [Pubmed]
  29. Molecular cloning of translocations involving chromosome 15 and the immunoglobulin C alpha gene from chromosome 12 in two murine plasmacytomas. Calame, K., Kim, S., Lalley, P., Hill, R., Davis, M., Hood, L. Proc. Natl. Acad. Sci. U.S.A. (1982) [Pubmed]
  30. Selective expression of intracisternal A-particle genes in established mouse plasmacytomas. Lueders, K.K., Fewell, J.W., Morozov, V.E., Kuff, E.L. Mol. Cell. Biol. (1993) [Pubmed]
  31. Purified mu EBP-E binds to immunoglobulin enhancers and promoters. Peterson, C.L., Eaton, S., Calame, K. Mol. Cell. Biol. (1988) [Pubmed]
  32. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Zukerberg, L.R., Benedict, W.F., Arnold, A., Dyson, N., Harlow, E., Harris, N.L. Blood (1996) [Pubmed]
WikiGenes - Universities